Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 in Advanced EGFR-High Non-Squamous NSCLC
NCT05215925Phase 2Unknown
- Sponsor
- Henlius
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Henlius. Status: unknown.
02
Drugs
pimurutamab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05215925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215925.